Episode III: The Future of Aging: Challenges & Opportunities

EVENT RECAP
October 1, 2021
Events

Please click on the banner image above to watch the dialogue.

“The most important thing that we can accomplish in the next number of years, and I certainly hope we make progress again on prevention and wellness. We make progress on scientific advancement. We make progress in technology. We make progress in our cultural norms. I think the most important thing that we could do is to address this challenge of ageism, because I think we recognize that all of us have a stake in ensuring that people stay healthier longer.” – Paul Irving

Episode III of the “Dialogues on Healthy Aging” features Paul Irving, Chairman, Milken Institute Center for the Future of Aging; Distinguished Scholar-in-Residence, USC Davis School of Gerontology with moderation by Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec.

Key discussions around:

– Why should we consider aging as a global crisis and a global challenge?

– What resources does the Milken Institute bring together to bridge the gaps in the effort to combat aging?

– How will technology such as tele-health and other digital technologies impact healthy aging in the future?

SPEAKERS

Paul Irving

CHAIRMAN, MILKEN INSTITUTE CENTER FOR THE FUTURE OF AGING; DISTINGUISHED SCHOLAR-IN-RESIDENCE, USC DAVIS SCHOOL OF GERONTOLOGY

Paul Irving is chairman of the Milken Institute Center for the Future of Aging, chairman of Encore.org, and distinguished scholar-in-residence at the University of Southern California Davis School of Gerontology. He previously served as the Milken Institute’s president, an advanced leadership fellow at Harvard University, and chairman and CEO of Manatt, Phelps & Phillips, LLP, a national law and consulting firm. Irving is a member of the Global Advisory Council of the Stanford University Distinguished Careers Institute, the Board of Councilors of the USC Davis School, the Global Coalition on Aging Advisory Council, the Advisory Board of WorkingNation, and the National Academy of Medicine Commission for Healthy Longevity. He also serves as a director of East West Bancorp, Inc. and on the International Strategic Committee of the Quadrivio Group Silver Economy Fund. Irving previously served on the Bipartisan Policy Center Senior Health and Housing Task Force and as a participant in the 2015 White House Conference on Aging. Author/editor of “The Upside of Aging: How Long Life Is Changing the World of Health, Work, Innovation, Policy, and Purpose,” a Wall Street Journal expert panelist and contributor to the Harvard Business Review and Forbes, PBS NextAvenue named Irving an “Influencer” for his work, and he was recognized with the Janet L. Witkin Humanitarian Award by Affordable Living for the Aging, the Life Journey Inspiration Award by Stanford’s Distinguished Careers Institute, and the Board of Governors Award by Loyola Law School, Los Angeles.

Richard Soll

HEAD OF BOSTON OFFICE AND SENIOR ADVISOR OF STRATEGIC INITIATIVES, WUXI APPTEC

Dr. Richard Soll is presently Senior Advisor, Strategic Initiatives for the Research Service Division at WuXi AppTec and Head of the WuXi office in Boston, Massachusetts. He has held various leadership roles at WuXi as Senior Vice President including head of the medicinal chemistry unit known as the International Discovery Service Unit, business development, and corporate alliances.

Dr. Soll’s contributions led to the discovery of the HCV NS5A inhibitor elbasvir (a component of Zepatier®) in the Merck-WuXi partnership, the JAK2 inhibitor fedratinib at TargeGen which formed the basis of the $7B partnership between Celgene and Impact Biomedicines, and more than 10 other clinical stage drugs throughout his career.

Dr. Soll is currently a board member at Simcha Therapeutics, an board observer at the Accelerator Life Science Parnters, and an advisory board member with the Blavatnik Center for Drug Discovery at Tel Aviv University, the Children’s Tumor Foundation, and the Pistoia Alliance.

Dr. Soll was CSO / VP of R&D at TargeGen and was VP of Chemistry at 3-Dimensional Pharmaceuticals. He started his career at Ayerst Research Labs and was trained as a synthetic chemist at Dartmouth and Harvard.

Subscribe to WXPress

Receive our newsletter and information on upcoming events.